Opthea (OPT) Appoints Sujal Shah to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Opthea Appoints Sujal Shah to the Board of Directors
April 3, 2024 5:39 PM EDTMELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT Opthea, the Company), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Sujal Shah to the Companys Board of Directors (the Board), effective April 4, 2024. Concurrent with his appointment as non-Executive Director, Mr. Shah will also become Chairman of the Audit and Risk Committee. In conjunction with Mr. Shahs appointment, the Company also announced that Daniel Spiegelman has resigned from the Board in his role as... More
